γδ T cells are involved in acute HIV infection and associated with AIDS progression

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Li, Zhen ^a   Li, Wei ^b   Li, Ning ^b   Jiao, Yanmei ^b   Chen, Dexi ^b   Cui, Lianxian ^a   Hu, Yu ^a   Wu, Hao ^b   He, Wei ^a  

^a PEKING UNION MEDICAL COLLEGE   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD14 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 17; ACUTE PHASE PROTEIN; CARRIER PROTEIN; LIPOPOLYSACCHARIDE; LIPOPOLYSACCHARIDE-BINDING PROTEIN; LYMPHOCYTE ANTIGEN RECEPTOR; MEMBRANE PROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CORRELATIONAL STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY ASSAY; DISEASE ASSOCIATION; DISEASE COURSE; EFFECTOR CELL; FLOW CYTOMETRY; GAMMA DELTA T LYMPHOCYTE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MEMORY T LYMPHOCYTE; MICROBIAL TRANSLOCATION; MICROBIOLOGICAL PHENOMENA AND FUNCTIONS; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; BLOOD; CASE CONTROL STUDY; CD4 CD8 RATIO; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; MICROBIOLOGY; PROSPECTIVE STUDY;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ACUTE-PHASE PROTEINS; ANTIGENS, CD14; CARRIER PROTEINS; CASE-CONTROL STUDIES; CD4-CD8 RATIO; DISEASE PROGRESSION; HIV INFECTIONS; HUMANS; LIPOPOLYSACCHARIDES; LYMPHOCYTE ACTIVATION; MALE; MEMBRANE GLYCOPROTEINS; PROSPECTIVE STUDIES; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; T-LYMPHOCYTE SUBSETS;

EID: 84907104270     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0106064     Document Type: Article

References (39)

1. Constant P, Davodeau F, Peyrat MA, Poquet Y, Puzo G, et al. (1994) Stimulation of human gamma delta T cells by nonpeptidic mycobacterial ligands. Science 264: 267-270.
2. Dik WA, Pike-Overzet K, Weerkamp F, de Ridder D, de Haas EF, et al. (2005) New insights on human T cell development by quantitative T cell receptor gene rearrangement studies and gene expression profiling. J Exp Med 201: 1715-1723.
3. Hayday AC (2000) [gamma][delta] cells: a right time and a right place for a conserved third way of protection. Annu Rev Immunol 18: 975-1026.
4. Xi X, Guo Y, Chen H, Xu C, Zhang H, et al. (2009) Antigen specificity of gammadelta T cells depends primarily on the flanking sequences of CDR3delta. J Biol Chem 284: 27449-27455.
5. Bukowski JF, Morita CT, Brenner MB (1999) Human gamma delta T cells recognize alkylamines derived from microbes, edible plants, and tea: implications for innate immunity. Immunity 11: 57-65.
6. Vincent MS, Roessner K, Sellati T, Huston CD, Sigal LH, et al. (1998) Lyme arthritis synovial gamma delta T cells respond to Borrelia burgdorferi lipoproteins and lipidated hexapeptides. J Immunol 161: 5762-5771.
7. Sanders JM, Ghosh S, Chan JM, Meints G, Wang H, et al. (2004) Quantitative structure-activity relationships for gammadelta T cell activation by bisphosphonates. J Med Chem 47: 375-384.
8. Battistini L, Caccamo N, Borsellino G, Meraviglia S, Angelini DF, et al. (2005) Homing and memory patterns of human gammadelta T cells in physiopathological situations. Microbes Infect 7: 510-517.
9. Qin G, Liu Y, Zheng J, Xiang Z, Ng IH, et al. (2012) Phenotypic and functional characterization of human gammadelta T-cell subsets in response to influenza A viruses. J Infect Dis 205: 1646-1653.
10. Dieli F, Poccia F, Lipp M, Sireci G, Caccamo N, et al. (2003) Differentiation of effector/memory Vdelta2 T cells and migratory routes in lymph nodes or inflammatory sites. J Exp Med 198: 391-397.
11. Eberl M, Engel R, Beck E, Jomaa H (2002) Differentiation of human gammadelta T cells towards distinct memory phenotypes. Cell Immunol 218: 1-6.
12. Ribot JC, deBarros A, Pang DJ, Neves JF, Peperzak V, et al. (2009) CD27 is a thymic determinant of the balance between interferon-gamma- and interleukin 17-producing gammadelta T cell subsets. Nat Immunol 10: 427-436.
13. Fenoglio D, Poggi A, Catellani S, Battaglia F, Ferrera A, et al. (2009) Vdelta1 T lymphocytes producing IFN-gamma and IL-17 are expanded in HIV-1-infected patients and respond to Candida albicans. Blood 113: 6611-6618.
14. Battistini L, Borsellino G, Sawicki G, Poccia F, Salvetti M, et al. (1997) Phenotypic and cytokine analysis of human peripheral blood gamma delta T cells expressing NK cell receptors. J Immunol 159: 3723-3730.
15. Brenchley JM, Douek DC (2012) Microbial translocation across the GI tract. Annu Rev Immunol 30: 149-173.
16. Santos-Oliveira JR, Regis EG, Giacoia-Gripp CB, Valverde JG, Alexandrino-de-Oliveira P, et al. (2013) Microbial translocation induces an intense proinflammatory response in patients with visceral leishmaniasis and HIV type 1 coinfection. J Infect Dis 208: 57-66.
17. Shibata K, Yamada H, Hara H, Kishihara K, Yoshikai Y (2007) Resident Vdelta1+ gammadelta T cells control early infiltration of neutrophils after Escherichia coli infection via IL-17 production. J Immunol 178: 4466-4472.
18. Schilbach K, Geiselhart A, Handgretinger R (2001) Induction of proliferation and augmented cytotoxicity of gammadelta T lymphocytes by bisphosphonate clodronate. Blood 97: 2917-2918.
19. Thedrez A, Harly C, Morice A, Salot S, Bonneville M, et al. (2009) IL-21-mediated potentiation of antitumor cytolytic and proinflammatory responses of human V gamma 9V delta 2 T cells for adoptive immunotherapy. J Immunol 182: 3423-3431.
20. Kotler DP, Gaetz HP, Lange M, Klein EB, Holt PR (1984) Enteropathy associated with the acquired immunodeficiency syndrome. Ann Intern Med 101: 421-428.
21. Epple HJ, Schneider T, Troeger H, Kunkel D, Allers K, et al. (2009) Impairment of the intestinal barrier is evident in untreated but absent in suppressively treated HIV-infected patients. Gut 58: 220-227.
22. Romero-Sanchez M, Gonzalez-Serna A, Pacheco YM, Ferrando-Martinez S, Machmach K, et al. (2012) Different biological significance of sCD14 and LPS in HIV-infection: importance of the immunovirology stage and association with HIV-disease progression markers. J Infect 65: 431-438.
23. Wittkop L, Bitard J, Lazaro E, Neau D, Bonnet F, et al. (2013) Effect of cytomegalovirus-induced immune response, self antigen-induced immune response, and microbial translocation on chronic immune activation in successfully treated HIV type 1-infected patients: the ANRS CO3 Aquitaine Cohort. J Infect Dis 207: 622-627.
24. Sandler NG, Wand H, Roque A, Law M, Nason MC, et al. (2011) Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis 203: 780-790.
25. Li H, Chaudhry S, Poonia B, Shao Y, Pauza CD (2013) Depletion and dysfunction of Vgamma2Vdelta2 T cells in HIV disease: mechanisms, impacts and therapeutic implications. Cell Mol Immunol 10: 42-49.
26. Li H, Peng H, Ma P, Ruan Y, Su B, et al. (2008) Association between Vgamma2Vdelta2 T cells and disease progression after infection with closely related strains of HIV in China. Clin Infect Dis 46: 1466-1472.
27. Zheng NN, McElrath MJ, Sow PS, Mesher A, Hawes SE, et al. (2011) Association between peripheral gammadelta T-cell profile and disease progression in individuals infected with HIV-1 or HIV-2 in West Africa. J Acquir Immune Defic Syndr 57: 92-100.
28. Bordon J, Evans PS, Propp N, Davis CE Jr, Redfield RR, et al. (2004) Association between longer duration of HIV-suppressive therapy and partial recovery of the V gamma 2 T cell receptor repertoire. J Infect Dis 189: 1482-1486.
29. Hebbeler AM, Propp N, Cairo C, Li H, Cummings JS, et al. (2008) Failure to restore the Vgamma2-Jgamma1.2 repertoire in HIV-infected men receiving highly active antiretroviral therapy (HAART). Clin Immunol 128: 349-357.
30. Zhou J, Kang N, Cui L, Ba D, He W (2012) Anti-gammadelta TCR antibody-expanded gammadelta T cells: a better choice for the adoptive immunotherapy of lymphoid malignancies. Cell Mol Immunol 9: 34-44.
31. Sodora DL, Silvestri G (2008) Immune activation and AIDS pathogenesis. AIDS 22: 439-446.
32. Deeks SG, Kitchen CM, Liu L, Guo H, Gascon R, et al. (2004) Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load. Blood 104: 942-947.
33. Chevalier MF, Petitjean G, Dunyach-Remy C, Didier C, Girard PM, et al. (2013) The Th17/Treg ratio, IL-1RA and sCD14 levels in primary HIV infection predict the T-cell activation set point in the absence of systemic microbial translocation. PLoS Pathog 9: e1003453.
34. Karim R, Mack WJ, Stiller T, Operskalski E, Frederick T, et al. (2013) Association of HIV clinical disease progression with profiles of early immune activation: results from a cluster analysis approach. AIDS 27: 1473-1481.
35. Alunno A, Bartoloni E, Bistoni O, Nocentini G, Ronchetti S, et al. (2012) Balance between regulatory T and Th17 cells in systemic lupus erythematosus: the old and the new. Clin Dev Immunol 2012: 823085.
36. Braga WM, Atanackovic D, Colleoni GW (2012) The role of regulatory T cells and TH17 cells in multiple myeloma. Clin Dev Immunol 2012: 293479.
37. Adib-Conquy M, Cavaillon JM (2007) Stress molecules in sepsis and systemic inflammatory response syndrome. FEBS Lett 581: 3723-3733.
38. Munoz C, Carlet J, Fitting C, Misset B, Bleriot JP, et al. (1991) Dysregulation of in vitro cytokine production by monocytes during sepsis. J Clin Invest 88: 1747-1754.
39. Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, et al. (2006) Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 12: 1365-1371.